# US 11,028,366 B2 · Methods of differentiating stem cells by modulating MIR-124

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,366 B2
- Document ID: US11028366B2
- Status: Granted
- Kind: B2
- Application number: 16/362,037
- Filed: 2019-03-22
- Published: 2019-07-11
- Granted: 2021-06-08
- Earliest claimed: 2012-11-30
- Assignees: Accelerated Biosciences Corp.
- Applicants: Accelerated BioSciences Corp.
- Inventors: Jau-Nan Lee; Tony Tung-Yin Lee; Yuta Lee
- Web page: https://patentgrep.com/patent/US11028366B2

## CPC

- C12N 5/0678: {Stem cells; Progenitor cells; Precursor cells}
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/04: for throat disorders
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/10: of the bladder
- A61P 15/02: for disorders of the vagina
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 25/02: for peripheral neuropathies
- A61P 27/02: Ophthalmic agents
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- G01N 33/5023: {on expression patterns}
- G01N 33/507: {Pancreatic cells}
- G01N 33/5073: {Stem cells}
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/65: MicroRNA
- C12N 2506/025: from extra-embryonic cells, e.g. trophoblast, placenta
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.

## Claims

### Claim 1

A method for increasing insulin production in a human in need thereof, comprising administering an isolated human pancreatic progenitor cell to the human in need thereof, wherein the isolated human pancreatic progenitor cell expresses insulin and betatrophin, whereby the insulin production in the human is increased in response to glucose stimulation in the human.

### Claim 2 (depends on 1)

The method of claim 1, wherein the isolated pancreatic progenitor cell further expresses C-peptide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the isolated pancreatic progenitor cell further expresses Ngn3.

### Claim 4 (depends on 1)

The method of claim 1, wherein the isolated pancreatic progenitor cell further expresses C-peptide and Ngn3.

### Claim 5 (depends on 1)

The method of claim 1, wherein the human in need thereof has one or more symptoms associated with diabetes.

### Claim 6 (depends on 5)

The method of claim 5, wherein the one or more symptoms is polyuria, polydipsia, polyphagia, weight loss, blurred vision, itchiness, peripheral neuropathy, recurrent vaginal infection, fatigue, slow healing of wounds, slow healing of sores, or any combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administering comprises injecting the isolated pancreatic progenitor cell to the human in need thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the administering comprises implanting the isolated pancreatic progenitor cell to the human in need thereof.